Molecular Cancer Targets Wester H Clin Cancer Res 2007;13:3470-3481.

Slides:

Advertisements

Similar presentations

Clinical developmentDiscovery Typical development timeline Typically – 8 yearsTypically 7 years.

Advertisements

In biochemical recurrence after curative treatment of prostate cancer, Choline PET/CT 1- has a detection rate of 10-20% when PSA: 1-2 ng/ml 2- has a detection.

INNOVAZIONI TERAPEUTICHE IN ONCOLOGIA MEDICA CAGLIARI GIUGNO 2005 LE TERAPIE A TARGET MOLECOLARE: UNA EVOLUZIONE EPOCALE DELLA TERAPIA ANTINEOPLASTICA.

Tumor Therapy with Monoclonal Antibodies

New Perspectives in Cancer Therapy Óren Smaletz Programa de Oncologia Hospital Israelita Albert Einstein.

KRAS testing in colorectal cancer: an overview. 2 What is KRAS? KRAS is a gene that encodes one of the proteins in the epidermal growth factor receptor.

Detection of Mutations in EGFR in Circulating Lung-Cancer Cells Colin Reisterer and Nick Swenson S. Maheswaran et al. The New England Journal of Medicine.

Genentech Research Early Development (gRED)

JHSGR 16 th April 2011 Dr Lee Man Kit Derek.  The value of PET in staging adenocarcinoma (e.g. colorectal cancer) is well established Tomoharu T. et.

Chapter 19 Cancer and the Immune System Dr. Capers.

Clinical Division of Oncology Department of Medicine I Medical University of Vienna, Austria Monoclonal antibodies in solid tumors.

Radionuclide methods in oncology Otto Lang, MD, PhD Otakar Bělohlávek, MD, CSc Dept Nucl Med Charles Univ, 3rd Med Fac Materials for medical students.

Understanding and Optimizing Treatment of Triple Negative Breast Cancer Edith Peterson Mitchell, MD, FACP Clinical Professor of Medicine and Medical Oncology.

MBBS Cancer Biology Module 2006 Tumour Vasculature and Therapeutic Strategies Barbara Pedley.

Epidermal Growth Factor Receptors (ErbB-1) and it’s role in Cancer By Jeron Fleming Photo retrieved from

PET/CT Imaging and Cancer Response to Treatment Dr. François Bénard.

Update on 18 F-Fluorodeoxyglucose/Positron Emission Tomography and Positron Emission Tomography/ Computed Tomography Imaging of Squamous Head and Neck.

Advances in Nuclear Medicine and its Impact on Diagnosis and Management of GI Cancers Medhat Osman, MD PhD Philip Alderson, MD.

Cancer: when our own cells become the enemy

Thorax / Lung Basic Science Conference 12/21/2005 J.R. Nitzkorski.

M. Wissmeyer Department of Nuclear Medicine, University of Berne (Inselspital) PET/CT in Radiation Oncology: Current Evidence and Future Perspectives.

New Developments in Cancer Treatment Dulcinea Quintana, MD.

Advanced Cancer Topics Journal Review 4/16/2009 AD.

Tumors Models, and Response of Tumors Martin Brown April 23, 2012

Diagnosis and treatment of neuroendocrine tumors Dan Granberg.

M. Wissmeyer Department of Nuclear Medicine, University of Berne (Inselspital) PET/CT in Oncology: PET Tracers other than FDG.

Imaging Questions in Ovarian Cancer Susanna I. Lee, MD, PhD.

Functional Imaging with PET for Sarcoma Rodney Hicks, MD, FRACP Director, Centre for Molecular Imaging Guy Toner, MD, FRACP Director, Medical Oncology.

Cancer, Oncogenes and Tumour suppressor Genes 1 Dr. Mohamed M. Sayed-Ahmed.

Phase 1 Study of ACE-041, a First-in-Class Inhibitor of Vascular Development in Patients with Advanced Solid and Hematologic Tumors N. G. Borgstein 1,

Expressing Surface Proteins to Target Cancer Cells Joe and Bobby.

Computational biology of cancer cell pathways Modelling of cancer cell function and response to therapy.

The Use of Anti-angiogenic Factors in the Treatment of Oncologic Disease Kyle Treesh, PA-S Bob Hadley, Ph.D., PA-C, Advisor University of Kentucky.

CANCER, ONCOGENES AND TUMOUR SUPPRESSOR GENES PHL 425 Dr. Mohamed M. Sayed-Ahmed 1/1/2015.

 Angiogenesis Signaling Cascades EGFR PI3K MAPK Nucleus Gene Activation Cell Cycle Progression M G1G1 S G2G2 Fos P P MAPK = mitogen-activated protein.

Oncology (onc- = tumor). Oncology (onco- = mass) -plasia = new development -trophy = growth –Changes in Growth sizeChanges in size of individual cell.

Adjuvant systemic therapy in breast cancer Targeted therapies Update R. Paridaens Belgian Breast Meeting

The highlight of resistance mechanism of targeted therapy on clinical therapy Zuhua Chen Dep. of GI oncology.

HOMING Ewing vs Paget Trapping vs homing (controlled arrest) “Seed and soil” Organ-specific metastatic colonization of favorable microenvironment.

ACRIN 6682 Phase II Trial OF 64 Cu-ATSM PET/CT in Cervical Cancer Principal Investigator: Farrokh Dehdashti, MD 10/4/08.

PET/MR in Oncology: Non– 18 F- FDG Tracers for Routine Applications R2 丁建鑫.

Oxygen and Cancer: friend or foe?. Part 1: Scientific part Dirk de Ruysscher Part 2: Organisational part Harald Moonen.

Therapy Targeted د. نورس نبيل جعفر أخصائية في علم الأورام طبيبة مشرفة بمشفى ابن النفيس مؤتمر نقابة أطباء سورية العلمي الأول.

Lung cancer Gene Kukuy, MD Cardiothoracic Surgery.

JESÚS SILVA-RODRÍGUEZ, PABLO AGUIAR, INÉS DOMÍNGUEZ-PRADO, MICHEL HERRANZ, ÁLVARO RUIBAL 18F-Choline: Is shine-through effect an issue for prostate SUV.

간담도 암에서의 PET 의 활용 핵의학과 홍일기. 18 F-FDG PET: Warburg effect.

A prospective study of PET/CT in initial staging of small-cell lung cancer : comparison with CT, bone scintigraphy and bone marrow analysis B. M. Fischer1,

Clinical and Research Updates in Gynecologic Oncology

Samsung Genome Institute Samsung Medical Center

Immune Keytruda.

Challenges for the treatment of breast cancer

PET Criteria for Response Assessment After Completion of Therapy for Aggressive NHL and HL Definition of a positive PET scan (Visual assessment is adequate,

Evolution of a “System” for Surgical Treatment of Adenocarcinomas

“CASE SERIES OF EGFR MUTATIONS IN SQUAMOUS CELL CARCINOMA LUNG ”

Patient Case 1 Patient Case 1: PET/CT Scan.

Meta-analysis of randomised phase III clinical trials comparing EGFR tyrosine kinase inhibitor (TKI) shows that male patients with non-small cell lung.

Figure 3 Intracranial targeting of high-grade gliomas

Figure 1 A schematic representation of the HER2 signalling pathway

The core pillars and thematic hallmarks of anti-tumour immunity governing response to immune checkpoint blockade Figure 2 from Cogdill et al. British.

Nat. Rev. Urol. doi: /nrurol

Molecular approaches to HER2 targeted therapy

The cancer stem cell concept in cancer progression and metastasis

Treatment Overview: The Multidisciplinary Team

Sequencing of targeted therapies in HER2-positive metastatic breast cancer Figure 2 from Singh et al. British Journal of Cancer (2014) 111,

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Representative CT and PET/CT images of three patients with NSCLCs

Clinical courses of patients.

MPGES is expressed in epithelial cells in benign and malignant tumors of the colon. mPGES is expressed in epithelial cells in benign and malignant tumors.

Patterns of clinical relapse and algorithm for the therapeutic strategy when AR to EGFR TKI occurs in patients with EGFR-mutant NSCLC. *After discussion.

Presentation transcript:

Molecular Cancer Targets Wester H Clin Cancer Res 2007;13:

Strengths of PET in Oncology 1. Improved Tumor Detection Only PET shows malignant intra-thoracic LN 2. Therapy Response Evaluation Lymphoma Ovarian carcinoma 3. Tumor Characterisation PET Baseline CT post R/ CT baseline Hypoxia Tumour Vasculature PET post R/ Wester, Clin Cancer Res Stromal Characterisation Bergers & Benjamin, Nat Rev Cancer 2003Carroll & Ashcroft, Exp Rev Mol Med, 2005

Characterisation of Cancer Hallmarks Hanahan & Weinberg, Cell 2000 Wester H Clin Cancer Res 2007 αVβ6 - 5nm affinity ligand Deroose et al., 2010, to be submitted Hausner et al.,Cancer Res 2009 Bauwens et al., 2009, abstract Interreg Apoptosis Imaging ApoptosisNo Apoptosis Imaging Angiogenesis Growth Receptor Imaging Dijkers et al, JNM 2009: Her2/neu Proliferation Imaging Imaging TGF-β signalling Kang et al, PNAS 2005 Imaging Tissue invasion NormalBlockage Imaging Metastasis Deroose et al., JNM 2007 Hanahan and Weinberg, Cell 2000

Novel PET Tracers for Cancer Diagnosis Ovarian carcinoma CT: Normal PET: Malignant Lymph Node FDG-PET /CT: Current State of the art BUT … FDG is not tumor specific Some tumors do not accumulate FDG Need for assessement of non- cytoreductive therapies Better Cancer Staging with FDG-PET/CT Evaluation of Novel 68 Ga-Labeled Receptor L igand PET/CT to Detect Ovarian Cancer Folate Receptor (FR) Fisher et al, JNM 2008 FR Scintigraphy 68 Ga-FR Ligand First in man Dosimetry 30 patients Correlation with post-op histology Malignant LN CT: Normal CT PET PET/CT Malignant LN Evaluation of 11 C-Choline PET/CT in Locally Advanced Prostate Cancer

PET and Therapy Response Assessement FDG-PET /CT: Current State of the art in lymphoma Therapy Response Evaluation with FDG-PET/CT Baseline Post R/ Residual Mass Cured PET CT Baseline Post R/ BUT … FDG is not tumor specific Some tumors do not accumulate FDG Response without complete remission in solid tumors Need for assessement of non-cytoreductive therapies Assessement of 90Y-DOTATOC Peptide R eceptor Radiation Therapy with 68GA-DOTATOC PET/CT Baseline Post R/ SS Receptor in NET “Theranostic” 68Ga/90Y-DOTATOC 68 Ga-DOTATOC PET/CT Post R/ Assessement of Anti-Angiogenic Therapy with Angiogenesis PET Deroose et al., 2010, to be submitted Bevacuzimab Baseline Cancer Bloodvessel Ligand Vessel PET

Multicenter Evaluation of PET as Response Predictor for Anti- EGFR Therapy in Metastatic Colorectal Cancer Van Cutsem et al, NEJM 2009 Prospective, multicenter trial to asses response to Cetuximab with PET 5 PET centers Tracer Production in Leuven

Ongoing Projects in Oncology Diagnostic performance of Choline PET in Prostate Cancer TR to Anti-angiogenic drugs in Colorectal Cancer TRE – RT planning in Colorectal Cancer TR to Anti-angiogenic Drugs in Colorectal Cancer Novel PET Tracer for Ovarian Cancer TRE to Medi551 in Non-Hodgkin Lymphoma (NHL) TRE to Proteasome Inhibitors in NHL TRE to Monoclonal Antibody in HL TRE to Monoclonal Antibody in NHL TRE to Anti-hormonal Therapy in Endometrial Cancer TRE to Small Molecule Her2Neu TKI in Breast Cancer TRE to Small Molecule Aurora Kinase Inhibitors in Sarcoma TRE to Multitarget Small Molecule TKI in Sarcoma TRE in NET after Peptide Receptor Radiation Therapy TRE in Pediatric Hodgkin’s Lymphoma (HL) Therapy Response Evaluation (TRE) in Lung Cancer (NSCLC) Academic Commercial